PRINCETON, N.J. & TOKYO & WALTHAM, Mass. — Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC); Otsuka Pharmaceutical, Co. Ltd. (Otsuka); and Visterra, Inc., an Otsuka group company announce that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for the investigational drug sibeprenlimab for the treatment of...
Latest News
Chengdu, China – Prof. Changyang Gong’s team (Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University) wrote this review, in which Dr. Xianzhou Huang leads most of the research. Rapid growth in nanoparticles as delivery systems holds vast promise to promote therapeutic approaches...
Montreal , Canada – UdeM’s Stéphanie Forté and co-researchers in Canada and Brazil have shown how people with sickle cell disease or sickle cell trait have a higher chance of dying from COVID-19 than the general population. Patients with sickle cell disease and carriers of the sickle cell trait, often...
Imagine glass shards being smashed relentlessly into your bones over and over again. That is what the pain of sickle cell disease feels like, a young girl once told Velvet Brown-Watts, who three years ago started a local support group for sickle cell patients and their families. “I thought that...
SEOUL, South Korea — SillaJen, Inc. (KOSDAQ: 215600) has submitted CSR to the US FDA on 06 Feb 2024 for REN026, a phase 1b/2a dose escalation and safety/efficacy evaluation study of Pexa-Vec in combination with cemiplimab in patients with metastatic or unresectable renal cell carcinoma (RCC). The study demonstrated an...
— Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, Florida — Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine...
Bochum, Germany – Diabetes often remains undetected until it has already damaged organs or nerves. This is partly due to the fact that diagnosis at an early stage is time-consuming and difficult. An international team of researchers headed by Associate Professor Dr. Johannes Dietrich from the Department of Medicine I...
San Diego, Calif. – Scientists at UC San Diego have developed a machine learning algorithm to simulate the time-consuming chemistry involved in the earliest phases of drug discovery, which could significantly streamline the process and open doors for never-before-seen treatments. Identifying candidate drugs for further optimization typically involves thousands of...
Pittsburgh, Pennsylvania – In Lambert-Eaton myasthenic syndrome (LEMS), patients’ immune systems attack a critical nerve cell protein, causing muscle weakness and degeneration. But not always — some patients lack antibodies to this protein, the calcium channel. Using the MCell simulation software developed in collaboration with the Pittsburgh Supercomputing Center (PSC),...
BEIJING, China — SineuGene Therapeutics, a clinical-stage biotechnology company focused on gene therapies for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its gene therapy, SNUG01, for the treatment of amyotrophic lateral sclerosis (ALS). SNUG01 is a first-in-class gene therapy targeting...